MedTrace Logo

Comparison of Combination Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer

NCT00066274 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-03-02

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying combination chemotherapy containing irinotecan and oxaliplatin to see how well it works compared to two standard combination chemotherapy regimens in treating patients with unresectable metastatic colorectal cancer.

Conditions

Interventions

DRUG

FOLFIRI regimen

DRUG

FOLFOX regimen

DRUG

fluorouracil

DRUG

irinotecan hydrochloride

DRUG

leucovorin calcium

DRUG

oxaliplatin

Sponsors & Collaborators

  • UNICANCER

    lead OTHER

Principal Investigators

  • Yves Becouarn, MD · Institut Bergonié

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-23
Primary Completion
2005-11-04
Completion
2007-04-01

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00066274 on ClinicalTrials.gov